nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Lacosamide—epilepsy syndrome	0.431	1	CrCtD
Dextroamphetamine—CYP2D6—epilepsy syndrome	0.0835	1	CbGaD
Dextroamphetamine—Lacosamide—Felbamate—epilepsy syndrome	0.0368	0.12	CrCrCtD
Dextroamphetamine—Phenformin—Lacosamide—epilepsy syndrome	0.0249	0.0815	CrCrCtD
Dextroamphetamine—Phenacemide—Felbamate—epilepsy syndrome	0.0249	0.0815	CrCrCtD
Dextroamphetamine—Lisdexamfetamine—Lacosamide—epilepsy syndrome	0.0249	0.0815	CrCrCtD
Dextroamphetamine—Nateglinide—Lacosamide—epilepsy syndrome	0.0222	0.0727	CrCrCtD
Dextroamphetamine—Aspartame—Lacosamide—epilepsy syndrome	0.0211	0.069	CrCrCtD
Dextroamphetamine—Bethanidine—Lacosamide—epilepsy syndrome	0.0192	0.0628	CrCrCtD
Dextroamphetamine—Mephentermine—Lacosamide—epilepsy syndrome	0.0184	0.0601	CrCrCtD
Dextroamphetamine—L-Phenylalanine—Felbamate—epilepsy syndrome	0.0184	0.0601	CrCrCtD
Dextroamphetamine—Phenelzine—Lacosamide—epilepsy syndrome	0.0177	0.0577	CrCrCtD
Dextroamphetamine—Phentermine—Lacosamide—epilepsy syndrome	0.017	0.0555	CrCrCtD
Dextroamphetamine—Phenacemide—Lacosamide—epilepsy syndrome	0.0143	0.0468	CrCrCtD
Dextroamphetamine—Amphetamine—Lacosamide—epilepsy syndrome	0.0139	0.0454	CrCrCtD
Dextroamphetamine—Methamphetamine—Lacosamide—epilepsy syndrome	0.0135	0.0441	CrCrCtD
Dextroamphetamine—L-Phenylalanine—Lacosamide—epilepsy syndrome	0.0106	0.0345	CrCrCtD
Dextroamphetamine—Benzphetamine—Phenytoin—epilepsy syndrome	0.0081	0.0265	CrCrCtD
Dextroamphetamine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00268	0.101	CbGeAlD
Dextroamphetamine—SLC18A2—telencephalic ventricle—epilepsy syndrome	0.00208	0.0787	CbGeAlD
Dextroamphetamine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00157	0.0595	CbGeAlD
Dextroamphetamine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.00142	0.0538	CbGeAlD
Dextroamphetamine—SLC18A2—ganglion—epilepsy syndrome	0.00129	0.049	CbGeAlD
Dextroamphetamine—SLC6A3—ganglion—epilepsy syndrome	0.000979	0.0371	CbGeAlD
Dextroamphetamine—TAAR1—nervous system—epilepsy syndrome	0.000868	0.0328	CbGeAlD
Dextroamphetamine—TAAR1—central nervous system—epilepsy syndrome	0.000835	0.0316	CbGeAlD
Dextroamphetamine—SLC6A2—ganglion—epilepsy syndrome	0.00079	0.0299	CbGeAlD
Dextroamphetamine—SLC6A3—hindbrain—epilepsy syndrome	0.000743	0.0281	CbGeAlD
Dextroamphetamine—SLC18A2—brainstem—epilepsy syndrome	0.000563	0.0213	CbGeAlD
Dextroamphetamine—ADRA1A—hindbrain—epilepsy syndrome	0.000557	0.0211	CbGeAlD
Dextroamphetamine—SLC18A2—forebrain—epilepsy syndrome	0.000543	0.0206	CbGeAlD
Dextroamphetamine—SLC18A2—telencephalon—epilepsy syndrome	0.000499	0.0189	CbGeAlD
Dextroamphetamine—SLC6A3—brainstem—epilepsy syndrome	0.000426	0.0161	CbGeAlD
Dextroamphetamine—SLC6A3—forebrain—epilepsy syndrome	0.000411	0.0155	CbGeAlD
Dextroamphetamine—SLC18A2—medulla oblongata—epilepsy syndrome	0.000392	0.0148	CbGeAlD
Dextroamphetamine—SLC6A3—telencephalon—epilepsy syndrome	0.000378	0.0143	CbGeAlD
Dextroamphetamine—SLC18A2—midbrain—epilepsy syndrome	0.000359	0.0136	CbGeAlD
Dextroamphetamine—SLC6A2—brainstem—epilepsy syndrome	0.000343	0.013	CbGeAlD
Dextroamphetamine—SLC6A2—forebrain—epilepsy syndrome	0.000331	0.0125	CbGeAlD
Dextroamphetamine—CYP2D6—hindbrain—epilepsy syndrome	0.000328	0.0124	CbGeAlD
Dextroamphetamine—ADRA1A—brainstem—epilepsy syndrome	0.000319	0.0121	CbGeAlD
Dextroamphetamine—ADRA1B—head—epilepsy syndrome	0.000314	0.0119	CbGeAlD
Dextroamphetamine—SLC18A2—head—epilepsy syndrome	0.000311	0.0118	CbGeAlD
Dextroamphetamine—ADRA1A—forebrain—epilepsy syndrome	0.000308	0.0117	CbGeAlD
Dextroamphetamine—SLC6A2—telencephalon—epilepsy syndrome	0.000305	0.0115	CbGeAlD
Dextroamphetamine—ADRA1B—nervous system—epilepsy syndrome	0.000298	0.0113	CbGeAlD
Dextroamphetamine—SLC18A2—nervous system—epilepsy syndrome	0.000295	0.0112	CbGeAlD
Dextroamphetamine—ADRA1B—central nervous system—epilepsy syndrome	0.000287	0.0108	CbGeAlD
Dextroamphetamine—SLC18A2—central nervous system—epilepsy syndrome	0.000284	0.0107	CbGeAlD
Dextroamphetamine—ADRA1A—telencephalon—epilepsy syndrome	0.000283	0.0107	CbGeAlD
Dextroamphetamine—SLC18A2—cerebellum—epilepsy syndrome	0.000277	0.0105	CbGeAlD
Dextroamphetamine—SLC6A3—midbrain—epilepsy syndrome	0.000271	0.0103	CbGeAlD
Dextroamphetamine—SLC6A3—spinal cord—epilepsy syndrome	0.000265	0.01	CbGeAlD
Dextroamphetamine—Phenacemide—SCN1A—epilepsy syndrome	0.000262	0.117	CrCbGaD
Dextroamphetamine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000239	0.00906	CbGeAlD
Dextroamphetamine—SLC6A3—head—epilepsy syndrome	0.000235	0.0089	CbGeAlD
Dextroamphetamine—Aspartame—TRPV1—epilepsy syndrome	0.000233	0.104	CrCbGaD
Dextroamphetamine—ADRA1B—brain—epilepsy syndrome	0.000228	0.00861	CbGeAlD
Dextroamphetamine—SLC18A2—brain—epilepsy syndrome	0.000225	0.00853	CbGeAlD
Dextroamphetamine—SLC6A3—nervous system—epilepsy syndrome	0.000223	0.00844	CbGeAlD
Dextroamphetamine—SLC6A3—central nervous system—epilepsy syndrome	0.000215	0.00813	CbGeAlD
Dextroamphetamine—SLC6A3—cerebellum—epilepsy syndrome	0.00021	0.00794	CbGeAlD
Dextroamphetamine—SLC6A2—head—epilepsy syndrome	0.00019	0.00718	CbGeAlD
Dextroamphetamine—CYP2D6—brainstem—epilepsy syndrome	0.000188	0.00712	CbGeAlD
Dextroamphetamine—Lacosamide—SCN9A—epilepsy syndrome	0.000182	0.0807	CrCbGaD
Dextroamphetamine—CYP2D6—forebrain—epilepsy syndrome	0.000181	0.00687	CbGeAlD
Dextroamphetamine—SLC6A2—nervous system—epilepsy syndrome	0.00018	0.00681	CbGeAlD
Dextroamphetamine—ADRA1A—head—epilepsy syndrome	0.000176	0.00668	CbGeAlD
Dextroamphetamine—Lacosamide—SCN3A—epilepsy syndrome	0.000174	0.0772	CrCbGaD
Dextroamphetamine—SLC6A2—central nervous system—epilepsy syndrome	0.000173	0.00656	CbGeAlD
Dextroamphetamine—SLC6A3—brain—epilepsy syndrome	0.00017	0.00645	CbGeAlD
Dextroamphetamine—ADRA1A—nervous system—epilepsy syndrome	0.000167	0.00633	CbGeAlD
Dextroamphetamine—CYP2D6—telencephalon—epilepsy syndrome	0.000167	0.00632	CbGeAlD
Dextroamphetamine—ADRA1A—central nervous system—epilepsy syndrome	0.000161	0.00609	CbGeAlD
Dextroamphetamine—Phenelzine—ABAT—epilepsy syndrome	0.000159	0.0705	CrCbGaD
Dextroamphetamine—ADRA1A—cerebellum—epilepsy syndrome	0.000157	0.00596	CbGeAlD
Dextroamphetamine—SLC6A2—brain—epilepsy syndrome	0.000138	0.0052	CbGeAlD
Dextroamphetamine—ADRA1A—brain—epilepsy syndrome	0.000128	0.00484	CbGeAlD
Dextroamphetamine—L-Phenylalanine—TH—epilepsy syndrome	0.00012	0.0531	CrCbGaD
Dextroamphetamine—Lacosamide—CA4—epilepsy syndrome	0.000114	0.0509	CrCbGaD
Dextroamphetamine—CYP2D6—head—epilepsy syndrome	0.000104	0.00393	CbGeAlD
Dextroamphetamine—CYP2D6—nervous system—epilepsy syndrome	9.85e-05	0.00373	CbGeAlD
Dextroamphetamine—CYP2D6—central nervous system—epilepsy syndrome	9.49e-05	0.00359	CbGeAlD
Dextroamphetamine—CYP2D6—cerebellum—epilepsy syndrome	9.27e-05	0.00351	CbGeAlD
Dextroamphetamine—Nateglinide—KCNJ11—epilepsy syndrome	8.59e-05	0.0382	CrCbGaD
Dextroamphetamine—CYP2D6—brain—epilepsy syndrome	7.53e-05	0.00285	CbGeAlD
Dextroamphetamine—Tolazoline—ADRA2A—epilepsy syndrome	6.93e-05	0.0308	CrCbGaD
Dextroamphetamine—Ephedrine—BCHE—epilepsy syndrome	6.6e-05	0.0293	CrCbGaD
Dextroamphetamine—Phenylpropanolamine—ADRA2A—epilepsy syndrome	6.05e-05	0.0269	CrCbGaD
Dextroamphetamine—Constipation—Lamotrigine—epilepsy syndrome	5.2e-05	0.000555	CcSEcCtD
Dextroamphetamine—Nervousness—Pregabalin—epilepsy syndrome	5.2e-05	0.000555	CcSEcCtD
Dextroamphetamine—Nausea—Acetazolamide—epilepsy syndrome	5.2e-05	0.000555	CcSEcCtD
Dextroamphetamine—Dizziness—Levetiracetam—epilepsy syndrome	5.19e-05	0.000554	CcSEcCtD
Dextroamphetamine—Body temperature increased—Oxcarbazepine—epilepsy syndrome	5.19e-05	0.000554	CcSEcCtD
Dextroamphetamine—Abdominal pain—Oxcarbazepine—epilepsy syndrome	5.19e-05	0.000554	CcSEcCtD
Dextroamphetamine—Diarrhoea—Fosphenytoin—epilepsy syndrome	5.19e-05	0.000554	CcSEcCtD
Dextroamphetamine—Vomiting—Propofol—epilepsy syndrome	5.17e-05	0.000552	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	5.15e-05	0.00055	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Topiramate—epilepsy syndrome	5.14e-05	0.000549	CcSEcCtD
Dextroamphetamine—Rash—Propofol—epilepsy syndrome	5.13e-05	0.000547	CcSEcCtD
Dextroamphetamine—Dermatitis—Propofol—epilepsy syndrome	5.12e-05	0.000547	CcSEcCtD
Dextroamphetamine—Hypertension—Valproic Acid—epilepsy syndrome	5.12e-05	0.000546	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—ADRA2A—epilepsy syndrome	5.12e-05	0.0227	CrCbGaD
Dextroamphetamine—Headache—Propofol—epilepsy syndrome	5.09e-05	0.000543	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Zonisamide—epilepsy syndrome	5.08e-05	0.000542	CcSEcCtD
Dextroamphetamine—Vomiting—Midazolam—epilepsy syndrome	5.06e-05	0.00054	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vigabatrin—epilepsy syndrome	5.06e-05	0.00054	CcSEcCtD
Dextroamphetamine—Asthenia—Felbamate—epilepsy syndrome	5.05e-05	0.000539	CcSEcCtD
Dextroamphetamine—Chest pain—Valproic Acid—epilepsy syndrome	5.04e-05	0.000538	CcSEcCtD
Dextroamphetamine—Anxiety—Valproic Acid—epilepsy syndrome	5.03e-05	0.000537	CcSEcCtD
Dextroamphetamine—Tremor—Pregabalin—epilepsy syndrome	5.02e-05	0.000536	CcSEcCtD
Dextroamphetamine—Rash—Midazolam—epilepsy syndrome	5.01e-05	0.000535	CcSEcCtD
Dextroamphetamine—Dizziness—Fosphenytoin—epilepsy syndrome	5.01e-05	0.000535	CcSEcCtD
Dextroamphetamine—Dermatitis—Midazolam—epilepsy syndrome	5.01e-05	0.000535	CcSEcCtD
Dextroamphetamine—Urticaria—Carbamazepine—epilepsy syndrome	5e-05	0.000534	CcSEcCtD
Dextroamphetamine—Vomiting—Levetiracetam—epilepsy syndrome	4.99e-05	0.000533	CcSEcCtD
Dextroamphetamine—Headache—Midazolam—epilepsy syndrome	4.98e-05	0.000532	CcSEcCtD
Dextroamphetamine—Abdominal pain—Carbamazepine—epilepsy syndrome	4.98e-05	0.000531	CcSEcCtD
Dextroamphetamine—Body temperature increased—Carbamazepine—epilepsy syndrome	4.98e-05	0.000531	CcSEcCtD
Dextroamphetamine—Diarrhoea—Diazepam—epilepsy syndrome	4.98e-05	0.000531	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	4.98e-05	0.000531	CcSEcCtD
Dextroamphetamine—Rash—Levetiracetam—epilepsy syndrome	4.95e-05	0.000529	CcSEcCtD
Dextroamphetamine—Dermatitis—Levetiracetam—epilepsy syndrome	4.95e-05	0.000528	CcSEcCtD
Dextroamphetamine—Asthenia—Zonisamide—epilepsy syndrome	4.94e-05	0.000528	CcSEcCtD
Dextroamphetamine—Dry mouth—Valproic Acid—epilepsy syndrome	4.93e-05	0.000527	CcSEcCtD
Dextroamphetamine—Agitation—Pregabalin—epilepsy syndrome	4.92e-05	0.000525	CcSEcCtD
Dextroamphetamine—Headache—Levetiracetam—epilepsy syndrome	4.92e-05	0.000525	CcSEcCtD
Dextroamphetamine—Angioedema—Pregabalin—epilepsy syndrome	4.89e-05	0.000522	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Clonazepam—epilepsy syndrome	4.89e-05	0.000522	CcSEcCtD
Dextroamphetamine—Dizziness—Vigabatrin—epilepsy syndrome	4.89e-05	0.000521	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Phenytoin—epilepsy syndrome	4.86e-05	0.000519	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—TNF—epilepsy syndrome	4.85e-05	0.0216	CrCbGaD
Dextroamphetamine—Anaphylactic shock—Valproic Acid—epilepsy syndrome	4.84e-05	0.000516	CcSEcCtD
Dextroamphetamine—Urticaria—Lamotrigine—epilepsy syndrome	4.83e-05	0.000516	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	4.83e-05	0.000516	CcSEcCtD
Dextroamphetamine—Nausea—Propofol—epilepsy syndrome	4.83e-05	0.000515	CcSEcCtD
Dextroamphetamine—Tension—Gabapentin—epilepsy syndrome	4.82e-05	0.000514	CcSEcCtD
Dextroamphetamine—Vomiting—Fosphenytoin—epilepsy syndrome	4.82e-05	0.000514	CcSEcCtD
Dextroamphetamine—Diarrhoea—Felbamate—epilepsy syndrome	4.82e-05	0.000514	CcSEcCtD
Dextroamphetamine—Abdominal pain—Lamotrigine—epilepsy syndrome	4.81e-05	0.000513	CcSEcCtD
Dextroamphetamine—Body temperature increased—Lamotrigine—epilepsy syndrome	4.81e-05	0.000513	CcSEcCtD
Dextroamphetamine—Dizziness—Diazepam—epilepsy syndrome	4.81e-05	0.000513	CcSEcCtD
Dextroamphetamine—Infection—Valproic Acid—epilepsy syndrome	4.8e-05	0.000513	CcSEcCtD
Dextroamphetamine—Rash—Fosphenytoin—epilepsy syndrome	4.78e-05	0.00051	CcSEcCtD
Dextroamphetamine—Dermatitis—Fosphenytoin—epilepsy syndrome	4.77e-05	0.00051	CcSEcCtD
Dextroamphetamine—Nervousness—Gabapentin—epilepsy syndrome	4.77e-05	0.000509	CcSEcCtD
Dextroamphetamine—Asthenia—Clonazepam—epilepsy syndrome	4.76e-05	0.000509	CcSEcCtD
Dextroamphetamine—Headache—Fosphenytoin—epilepsy syndrome	4.75e-05	0.000507	CcSEcCtD
Dextroamphetamine—Palpitations—Pregabalin—epilepsy syndrome	4.73e-05	0.000505	CcSEcCtD
Dextroamphetamine—Asthenia—Phenytoin—epilepsy syndrome	4.73e-05	0.000505	CcSEcCtD
Dextroamphetamine—Nausea—Midazolam—epilepsy syndrome	4.72e-05	0.000504	CcSEcCtD
Dextroamphetamine—Tachycardia—Valproic Acid—epilepsy syndrome	4.72e-05	0.000504	CcSEcCtD
Dextroamphetamine—Diarrhoea—Zonisamide—epilepsy syndrome	4.71e-05	0.000503	CcSEcCtD
Dextroamphetamine—Asthenia—Oxcarbazepine—epilepsy syndrome	4.71e-05	0.000502	CcSEcCtD
Dextroamphetamine—Vomiting—Vigabatrin—epilepsy syndrome	4.7e-05	0.000501	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Valproic Acid—epilepsy syndrome	4.68e-05	0.000499	CcSEcCtD
Dextroamphetamine—Nausea—Levetiracetam—epilepsy syndrome	4.66e-05	0.000498	CcSEcCtD
Dextroamphetamine—Rash—Vigabatrin—epilepsy syndrome	4.66e-05	0.000497	CcSEcCtD
Dextroamphetamine—Tranylcypromine—CYP2C19—epilepsy syndrome	4.66e-05	0.0207	CrCbGaD
Dextroamphetamine—Dizziness—Felbamate—epilepsy syndrome	4.66e-05	0.000497	CcSEcCtD
Dextroamphetamine—Dermatitis—Vigabatrin—epilepsy syndrome	4.65e-05	0.000497	CcSEcCtD
Dextroamphetamine—Convulsion—Pregabalin—epilepsy syndrome	4.64e-05	0.000495	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Carbamazepine—epilepsy syndrome	4.64e-05	0.000495	CcSEcCtD
Dextroamphetamine—Headache—Vigabatrin—epilepsy syndrome	4.63e-05	0.000494	CcSEcCtD
Dextroamphetamine—Hypertension—Pregabalin—epilepsy syndrome	4.62e-05	0.000494	CcSEcCtD
Dextroamphetamine—Vomiting—Diazepam—epilepsy syndrome	4.62e-05	0.000494	CcSEcCtD
Dextroamphetamine—Anorexia—Valproic Acid—epilepsy syndrome	4.61e-05	0.000492	CcSEcCtD
Dextroamphetamine—Tremor—Gabapentin—epilepsy syndrome	4.6e-05	0.000491	CcSEcCtD
Dextroamphetamine—Rash—Diazepam—epilepsy syndrome	4.59e-05	0.000489	CcSEcCtD
Dextroamphetamine—Dermatitis—Diazepam—epilepsy syndrome	4.58e-05	0.000489	CcSEcCtD
Dextroamphetamine—Chest pain—Pregabalin—epilepsy syndrome	4.56e-05	0.000487	CcSEcCtD
Dextroamphetamine—Dizziness—Zonisamide—epilepsy syndrome	4.56e-05	0.000486	CcSEcCtD
Dextroamphetamine—Headache—Diazepam—epilepsy syndrome	4.56e-05	0.000486	CcSEcCtD
Dextroamphetamine—Anxiety—Pregabalin—epilepsy syndrome	4.54e-05	0.000485	CcSEcCtD
Dextroamphetamine—Diarrhoea—Clonazepam—epilepsy syndrome	4.54e-05	0.000485	CcSEcCtD
Dextroamphetamine—Asthenia—Carbamazepine—epilepsy syndrome	4.52e-05	0.000482	CcSEcCtD
Dextroamphetamine—Agitation—Gabapentin—epilepsy syndrome	4.51e-05	0.000482	CcSEcCtD
Dextroamphetamine—Diarrhoea—Phenytoin—epilepsy syndrome	4.51e-05	0.000482	CcSEcCtD
Dextroamphetamine—Nausea—Fosphenytoin—epilepsy syndrome	4.5e-05	0.000481	CcSEcCtD
Dextroamphetamine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	4.49e-05	0.000479	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Topiramate—epilepsy syndrome	4.49e-05	0.000479	CcSEcCtD
Dextroamphetamine—Angioedema—Gabapentin—epilepsy syndrome	4.49e-05	0.000479	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Lamotrigine—epilepsy syndrome	4.48e-05	0.000479	CcSEcCtD
Dextroamphetamine—Vomiting—Felbamate—epilepsy syndrome	4.48e-05	0.000478	CcSEcCtD
Dextroamphetamine—Dry mouth—Pregabalin—epilepsy syndrome	4.46e-05	0.000476	CcSEcCtD
Dextroamphetamine—Rash—Felbamate—epilepsy syndrome	4.44e-05	0.000474	CcSEcCtD
Dextroamphetamine—Dermatitis—Felbamate—epilepsy syndrome	4.43e-05	0.000473	CcSEcCtD
Dextroamphetamine—Headache—Felbamate—epilepsy syndrome	4.41e-05	0.000471	CcSEcCtD
Dextroamphetamine—Dizziness—Clonazepam—epilepsy syndrome	4.39e-05	0.000469	CcSEcCtD
Dextroamphetamine—Nausea—Vigabatrin—epilepsy syndrome	4.39e-05	0.000468	CcSEcCtD
Dextroamphetamine—Vomiting—Zonisamide—epilepsy syndrome	4.38e-05	0.000468	CcSEcCtD
Dextroamphetamine—Insomnia—Valproic Acid—epilepsy syndrome	4.37e-05	0.000467	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Pregabalin—epilepsy syndrome	4.37e-05	0.000467	CcSEcCtD
Dextroamphetamine—Asthenia—Lamotrigine—epilepsy syndrome	4.37e-05	0.000466	CcSEcCtD
Dextroamphetamine—Dizziness—Phenytoin—epilepsy syndrome	4.36e-05	0.000466	CcSEcCtD
Dextroamphetamine—Rash—Zonisamide—epilepsy syndrome	4.34e-05	0.000464	CcSEcCtD
Dextroamphetamine—Infection—Pregabalin—epilepsy syndrome	4.34e-05	0.000464	CcSEcCtD
Dextroamphetamine—Palpitations—Gabapentin—epilepsy syndrome	4.34e-05	0.000463	CcSEcCtD
Dextroamphetamine—Dermatitis—Zonisamide—epilepsy syndrome	4.34e-05	0.000463	CcSEcCtD
Dextroamphetamine—Dizziness—Oxcarbazepine—epilepsy syndrome	4.34e-05	0.000463	CcSEcCtD
Dextroamphetamine—Nausea—Diazepam—epilepsy syndrome	4.32e-05	0.000461	CcSEcCtD
Dextroamphetamine—Headache—Zonisamide—epilepsy syndrome	4.32e-05	0.000461	CcSEcCtD
Dextroamphetamine—Dyspnoea—Valproic Acid—epilepsy syndrome	4.31e-05	0.00046	CcSEcCtD
Dextroamphetamine—Diarrhoea—Carbamazepine—epilepsy syndrome	4.31e-05	0.00046	CcSEcCtD
Dextroamphetamine—Somnolence—Valproic Acid—epilepsy syndrome	4.3e-05	0.000459	CcSEcCtD
Dextroamphetamine—Tachycardia—Pregabalin—epilepsy syndrome	4.27e-05	0.000455	CcSEcCtD
Dextroamphetamine—Dyspepsia—Valproic Acid—epilepsy syndrome	4.26e-05	0.000454	CcSEcCtD
Dextroamphetamine—Convulsion—Gabapentin—epilepsy syndrome	4.26e-05	0.000454	CcSEcCtD
Dextroamphetamine—Hypertension—Gabapentin—epilepsy syndrome	4.24e-05	0.000453	CcSEcCtD
Dextroamphetamine—Phenformin—CYP2D6—epilepsy syndrome	4.23e-05	0.0188	CrCbGaD
Dextroamphetamine—Hyperhidrosis—Pregabalin—epilepsy syndrome	4.23e-05	0.000451	CcSEcCtD
Dextroamphetamine—Vomiting—Clonazepam—epilepsy syndrome	4.22e-05	0.000451	CcSEcCtD
Dextroamphetamine—Decreased appetite—Valproic Acid—epilepsy syndrome	4.2e-05	0.000449	CcSEcCtD
Dextroamphetamine—Vomiting—Phenytoin—epilepsy syndrome	4.19e-05	0.000448	CcSEcCtD
Dextroamphetamine—Rash—Clonazepam—epilepsy syndrome	4.19e-05	0.000447	CcSEcCtD
Dextroamphetamine—Dermatitis—Clonazepam—epilepsy syndrome	4.18e-05	0.000447	CcSEcCtD
Dextroamphetamine—Chest pain—Gabapentin—epilepsy syndrome	4.18e-05	0.000446	CcSEcCtD
Dextroamphetamine—Nausea—Felbamate—epilepsy syndrome	4.18e-05	0.000446	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	4.18e-05	0.000446	CcSEcCtD
Dextroamphetamine—Vomiting—Oxcarbazepine—epilepsy syndrome	4.17e-05	0.000445	CcSEcCtD
Dextroamphetamine—Fatigue—Valproic Acid—epilepsy syndrome	4.17e-05	0.000445	CcSEcCtD
Dextroamphetamine—Anxiety—Gabapentin—epilepsy syndrome	4.17e-05	0.000445	CcSEcCtD
Dextroamphetamine—Anorexia—Pregabalin—epilepsy syndrome	4.17e-05	0.000445	CcSEcCtD
Dextroamphetamine—Dizziness—Carbamazepine—epilepsy syndrome	4.16e-05	0.000444	CcSEcCtD
Dextroamphetamine—Diarrhoea—Lamotrigine—epilepsy syndrome	4.16e-05	0.000444	CcSEcCtD
Dextroamphetamine—Headache—Clonazepam—epilepsy syndrome	4.16e-05	0.000444	CcSEcCtD
Dextroamphetamine—Rash—Phenytoin—epilepsy syndrome	4.16e-05	0.000444	CcSEcCtD
Dextroamphetamine—Dermatitis—Phenytoin—epilepsy syndrome	4.16e-05	0.000444	CcSEcCtD
Dextroamphetamine—Rash—Oxcarbazepine—epilepsy syndrome	4.14e-05	0.000442	CcSEcCtD
Dextroamphetamine—Constipation—Valproic Acid—epilepsy syndrome	4.14e-05	0.000441	CcSEcCtD
Dextroamphetamine—Dermatitis—Oxcarbazepine—epilepsy syndrome	4.13e-05	0.000441	CcSEcCtD
Dextroamphetamine—Headache—Phenytoin—epilepsy syndrome	4.13e-05	0.000441	CcSEcCtD
Dextroamphetamine—Phentermine—SLC6A4—epilepsy syndrome	4.12e-05	0.0183	CrCbGaD
Dextroamphetamine—Headache—Oxcarbazepine—epilepsy syndrome	4.11e-05	0.000439	CcSEcCtD
Dextroamphetamine—Nausea—Zonisamide—epilepsy syndrome	4.09e-05	0.000437	CcSEcCtD
Dextroamphetamine—Dry mouth—Gabapentin—epilepsy syndrome	4.09e-05	0.000437	CcSEcCtD
Dextroamphetamine—Tension—Topiramate—epilepsy syndrome	4.06e-05	0.000433	CcSEcCtD
Dextroamphetamine—Dizziness—Lamotrigine—epilepsy syndrome	4.02e-05	0.00043	CcSEcCtD
Dextroamphetamine—Nervousness—Topiramate—epilepsy syndrome	4.01e-05	0.000428	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Gabapentin—epilepsy syndrome	4.01e-05	0.000428	CcSEcCtD
Dextroamphetamine—Vomiting—Carbamazepine—epilepsy syndrome	4e-05	0.000427	CcSEcCtD
Dextroamphetamine—Infection—Gabapentin—epilepsy syndrome	3.98e-05	0.000425	CcSEcCtD
Dextroamphetamine—Rash—Carbamazepine—epilepsy syndrome	3.97e-05	0.000424	CcSEcCtD
Dextroamphetamine—Dermatitis—Carbamazepine—epilepsy syndrome	3.97e-05	0.000423	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.95e-05	0.000422	CcSEcCtD
Dextroamphetamine—Insomnia—Pregabalin—epilepsy syndrome	3.95e-05	0.000422	CcSEcCtD
Dextroamphetamine—Nausea—Clonazepam—epilepsy syndrome	3.94e-05	0.000421	CcSEcCtD
Dextroamphetamine—Headache—Carbamazepine—epilepsy syndrome	3.94e-05	0.000421	CcSEcCtD
Dextroamphetamine—Nausea—Phenytoin—epilepsy syndrome	3.92e-05	0.000418	CcSEcCtD
Dextroamphetamine—Tachycardia—Gabapentin—epilepsy syndrome	3.91e-05	0.000418	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—SLC6A4—epilepsy syndrome	3.9e-05	0.0174	CrCbGaD
Dextroamphetamine—Dyspnoea—Pregabalin—epilepsy syndrome	3.9e-05	0.000416	CcSEcCtD
Dextroamphetamine—Nausea—Oxcarbazepine—epilepsy syndrome	3.9e-05	0.000416	CcSEcCtD
Dextroamphetamine—Somnolence—Pregabalin—epilepsy syndrome	3.89e-05	0.000415	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.88e-05	0.000414	CcSEcCtD
Dextroamphetamine—Tremor—Topiramate—epilepsy syndrome	3.87e-05	0.000413	CcSEcCtD
Dextroamphetamine—Vomiting—Lamotrigine—epilepsy syndrome	3.87e-05	0.000413	CcSEcCtD
Dextroamphetamine—Methamphetamine—ADRA2A—epilepsy syndrome	3.84e-05	0.0171	CrCbGaD
Dextroamphetamine—Urticaria—Valproic Acid—epilepsy syndrome	3.84e-05	0.00041	CcSEcCtD
Dextroamphetamine—Rash—Lamotrigine—epilepsy syndrome	3.84e-05	0.00041	CcSEcCtD
Dextroamphetamine—Dermatitis—Lamotrigine—epilepsy syndrome	3.83e-05	0.000409	CcSEcCtD
Dextroamphetamine—Body temperature increased—Valproic Acid—epilepsy syndrome	3.82e-05	0.000408	CcSEcCtD
Dextroamphetamine—Abdominal pain—Valproic Acid—epilepsy syndrome	3.82e-05	0.000408	CcSEcCtD
Dextroamphetamine—Anorexia—Gabapentin—epilepsy syndrome	3.82e-05	0.000408	CcSEcCtD
Dextroamphetamine—Benzphetamine—ADRA2A—epilepsy syndrome	3.81e-05	0.017	CrCbGaD
Dextroamphetamine—Headache—Lamotrigine—epilepsy syndrome	3.81e-05	0.000407	CcSEcCtD
Dextroamphetamine—Decreased appetite—Pregabalin—epilepsy syndrome	3.8e-05	0.000406	CcSEcCtD
Dextroamphetamine—Agitation—Topiramate—epilepsy syndrome	3.8e-05	0.000405	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.77e-05	0.000403	CcSEcCtD
Dextroamphetamine—Fatigue—Pregabalin—epilepsy syndrome	3.77e-05	0.000402	CcSEcCtD
Dextroamphetamine—Nausea—Carbamazepine—epilepsy syndrome	3.74e-05	0.000399	CcSEcCtD
Dextroamphetamine—Constipation—Pregabalin—epilepsy syndrome	3.74e-05	0.000399	CcSEcCtD
Dextroamphetamine—Palpitations—Topiramate—epilepsy syndrome	3.65e-05	0.00039	CcSEcCtD
Dextroamphetamine—Insomnia—Gabapentin—epilepsy syndrome	3.63e-05	0.000387	CcSEcCtD
Dextroamphetamine—Nausea—Lamotrigine—epilepsy syndrome	3.61e-05	0.000386	CcSEcCtD
Dextroamphetamine—Selegiline—CYP2C19—epilepsy syndrome	3.61e-05	0.0161	CrCbGaD
Dextroamphetamine—Convulsion—Topiramate—epilepsy syndrome	3.58e-05	0.000382	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3.58e-05	0.000382	CcSEcCtD
Dextroamphetamine—Dyspnoea—Gabapentin—epilepsy syndrome	3.57e-05	0.000381	CcSEcCtD
Dextroamphetamine—Hypertension—Topiramate—epilepsy syndrome	3.57e-05	0.000381	CcSEcCtD
Dextroamphetamine—Somnolence—Gabapentin—epilepsy syndrome	3.56e-05	0.00038	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.56e-05	0.00038	CcSEcCtD
Dextroamphetamine—Dyspepsia—Gabapentin—epilepsy syndrome	3.53e-05	0.000377	CcSEcCtD
Dextroamphetamine—Chest pain—Topiramate—epilepsy syndrome	3.52e-05	0.000376	CcSEcCtD
Dextroamphetamine—Anxiety—Topiramate—epilepsy syndrome	3.51e-05	0.000374	CcSEcCtD
Dextroamphetamine—Decreased appetite—Gabapentin—epilepsy syndrome	3.48e-05	0.000372	CcSEcCtD
Dextroamphetamine—Urticaria—Pregabalin—epilepsy syndrome	3.47e-05	0.000371	CcSEcCtD
Dextroamphetamine—Asthenia—Valproic Acid—epilepsy syndrome	3.47e-05	0.00037	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.46e-05	0.000369	CcSEcCtD
Dextroamphetamine—Fatigue—Gabapentin—epilepsy syndrome	3.46e-05	0.000369	CcSEcCtD
Dextroamphetamine—Abdominal pain—Pregabalin—epilepsy syndrome	3.46e-05	0.000369	CcSEcCtD
Dextroamphetamine—Body temperature increased—Pregabalin—epilepsy syndrome	3.46e-05	0.000369	CcSEcCtD
Dextroamphetamine—Tranylcypromine—CYP2D6—epilepsy syndrome	3.45e-05	0.0154	CrCbGaD
Dextroamphetamine—Dry mouth—Topiramate—epilepsy syndrome	3.44e-05	0.000367	CcSEcCtD
Dextroamphetamine—Constipation—Gabapentin—epilepsy syndrome	3.43e-05	0.000366	CcSEcCtD
Dextroamphetamine—Infection—Topiramate—epilepsy syndrome	3.35e-05	0.000358	CcSEcCtD
Dextroamphetamine—Diarrhoea—Valproic Acid—epilepsy syndrome	3.31e-05	0.000353	CcSEcCtD
Dextroamphetamine—Tachycardia—Topiramate—epilepsy syndrome	3.29e-05	0.000351	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	3.28e-05	0.00035	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Topiramate—epilepsy syndrome	3.26e-05	0.000348	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Pregabalin—epilepsy syndrome	3.22e-05	0.000344	CcSEcCtD
Dextroamphetamine—Anorexia—Topiramate—epilepsy syndrome	3.21e-05	0.000343	CcSEcCtD
Dextroamphetamine—Dizziness—Valproic Acid—epilepsy syndrome	3.2e-05	0.000341	CcSEcCtD
Dextroamphetamine—Urticaria—Gabapentin—epilepsy syndrome	3.18e-05	0.00034	CcSEcCtD
Dextroamphetamine—Phenelzine—CYP2C19—epilepsy syndrome	3.18e-05	0.0141	CrCbGaD
Dextroamphetamine—Body temperature increased—Gabapentin—epilepsy syndrome	3.17e-05	0.000338	CcSEcCtD
Dextroamphetamine—Abdominal pain—Gabapentin—epilepsy syndrome	3.17e-05	0.000338	CcSEcCtD
Dextroamphetamine—Amphetamine—SLC6A4—epilepsy syndrome	3.17e-05	0.0141	CrCbGaD
Dextroamphetamine—Asthenia—Pregabalin—epilepsy syndrome	3.14e-05	0.000335	CcSEcCtD
Dextroamphetamine—Vomiting—Valproic Acid—epilepsy syndrome	3.07e-05	0.000328	CcSEcCtD
Dextroamphetamine—Insomnia—Topiramate—epilepsy syndrome	3.05e-05	0.000326	CcSEcCtD
Dextroamphetamine—Rash—Valproic Acid—epilepsy syndrome	3.05e-05	0.000325	CcSEcCtD
Dextroamphetamine—Dermatitis—Valproic Acid—epilepsy syndrome	3.05e-05	0.000325	CcSEcCtD
Dextroamphetamine—Headache—Valproic Acid—epilepsy syndrome	3.03e-05	0.000323	CcSEcCtD
Dextroamphetamine—Dyspnoea—Topiramate—epilepsy syndrome	3.01e-05	0.000321	CcSEcCtD
Dextroamphetamine—Somnolence—Topiramate—epilepsy syndrome	3e-05	0.00032	CcSEcCtD
Dextroamphetamine—Diarrhoea—Pregabalin—epilepsy syndrome	2.99e-05	0.000319	CcSEcCtD
Dextroamphetamine—Dyspepsia—Topiramate—epilepsy syndrome	2.97e-05	0.000317	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Gabapentin—epilepsy syndrome	2.95e-05	0.000315	CcSEcCtD
Dextroamphetamine—Methamphetamine—SLC6A4—epilepsy syndrome	2.93e-05	0.013	CrCbGaD
Dextroamphetamine—Decreased appetite—Topiramate—epilepsy syndrome	2.93e-05	0.000313	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.91e-05	0.000311	CcSEcCtD
Dextroamphetamine—Fatigue—Topiramate—epilepsy syndrome	2.91e-05	0.00031	CcSEcCtD
Dextroamphetamine—Phentermine—CYP2D6—epilepsy syndrome	2.89e-05	0.0129	CrCbGaD
Dextroamphetamine—Dizziness—Pregabalin—epilepsy syndrome	2.89e-05	0.000309	CcSEcCtD
Dextroamphetamine—Constipation—Topiramate—epilepsy syndrome	2.88e-05	0.000308	CcSEcCtD
Dextroamphetamine—Asthenia—Gabapentin—epilepsy syndrome	2.88e-05	0.000307	CcSEcCtD
Dextroamphetamine—Nausea—Valproic Acid—epilepsy syndrome	2.87e-05	0.000307	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP2D6—epilepsy syndrome	2.79e-05	0.0124	CrCbGaD
Dextroamphetamine—Vomiting—Pregabalin—epilepsy syndrome	2.78e-05	0.000297	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.76e-05	0.000294	CcSEcCtD
Dextroamphetamine—Rash—Pregabalin—epilepsy syndrome	2.76e-05	0.000294	CcSEcCtD
Dextroamphetamine—Dermatitis—Pregabalin—epilepsy syndrome	2.75e-05	0.000294	CcSEcCtD
Dextroamphetamine—Diarrhoea—Gabapentin—epilepsy syndrome	2.74e-05	0.000293	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—CYP2D6—epilepsy syndrome	2.74e-05	0.0122	CrCbGaD
Dextroamphetamine—Headache—Pregabalin—epilepsy syndrome	2.74e-05	0.000292	CcSEcCtD
Dextroamphetamine—Urticaria—Topiramate—epilepsy syndrome	2.68e-05	0.000286	CcSEcCtD
Dextroamphetamine—Selegiline—CYP2D6—epilepsy syndrome	2.68e-05	0.0119	CrCbGaD
Dextroamphetamine—Abdominal pain—Topiramate—epilepsy syndrome	2.67e-05	0.000285	CcSEcCtD
Dextroamphetamine—Body temperature increased—Topiramate—epilepsy syndrome	2.67e-05	0.000285	CcSEcCtD
Dextroamphetamine—Dizziness—Gabapentin—epilepsy syndrome	2.65e-05	0.000283	CcSEcCtD
Dextroamphetamine—Nausea—Pregabalin—epilepsy syndrome	2.6e-05	0.000277	CcSEcCtD
Dextroamphetamine—Vomiting—Gabapentin—epilepsy syndrome	2.55e-05	0.000272	CcSEcCtD
Dextroamphetamine—Rash—Gabapentin—epilepsy syndrome	2.53e-05	0.00027	CcSEcCtD
Dextroamphetamine—Dermatitis—Gabapentin—epilepsy syndrome	2.53e-05	0.00027	CcSEcCtD
Dextroamphetamine—Headache—Gabapentin—epilepsy syndrome	2.51e-05	0.000268	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Topiramate—epilepsy syndrome	2.48e-05	0.000265	CcSEcCtD
Dextroamphetamine—Asthenia—Topiramate—epilepsy syndrome	2.42e-05	0.000258	CcSEcCtD
Dextroamphetamine—Nateglinide—CYP2D6—epilepsy syndrome	2.39e-05	0.0106	CrCbGaD
Dextroamphetamine—Nausea—Gabapentin—epilepsy syndrome	2.38e-05	0.000254	CcSEcCtD
Dextroamphetamine—Diarrhoea—Topiramate—epilepsy syndrome	2.31e-05	0.000246	CcSEcCtD
Dextroamphetamine—Dizziness—Topiramate—epilepsy syndrome	2.23e-05	0.000238	CcSEcCtD
Dextroamphetamine—Amphetamine—CYP2D6—epilepsy syndrome	2.22e-05	0.00989	CrCbGaD
Dextroamphetamine—Vomiting—Topiramate—epilepsy syndrome	2.14e-05	0.000229	CcSEcCtD
Dextroamphetamine—Rash—Topiramate—epilepsy syndrome	2.13e-05	0.000227	CcSEcCtD
Dextroamphetamine—Dermatitis—Topiramate—epilepsy syndrome	2.12e-05	0.000227	CcSEcCtD
Dextroamphetamine—Headache—Topiramate—epilepsy syndrome	2.11e-05	0.000226	CcSEcCtD
Dextroamphetamine—Methamphetamine—CYP2D6—epilepsy syndrome	2.06e-05	0.00917	CrCbGaD
Dextroamphetamine—Nausea—Topiramate—epilepsy syndrome	2e-05	0.000214	CcSEcCtD
Dextroamphetamine—Selegiline—ABCB1—epilepsy syndrome	1.91e-05	0.0085	CrCbGaD
Dextroamphetamine—Nateglinide—ALB—epilepsy syndrome	1.79e-05	0.00796	CrCbGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL12—epilepsy syndrome	5.01e-06	8.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—BDKRB2—epilepsy syndrome	5.01e-06	8.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PLCB1—epilepsy syndrome	5.01e-06	8.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CHRM1—epilepsy syndrome	4.99e-06	8.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRM1—epilepsy syndrome	4.99e-06	8.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDYN—epilepsy syndrome	4.99e-06	8.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR7—epilepsy syndrome	4.99e-06	8.78e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NEU1—epilepsy syndrome	4.98e-06	8.76e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ATIC—epilepsy syndrome	4.98e-06	8.76e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—UPB1—epilepsy syndrome	4.98e-06	8.76e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CNR1—epilepsy syndrome	4.91e-06	8.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR7—epilepsy syndrome	4.9e-06	8.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PLCB1—epilepsy syndrome	4.9e-06	8.61e-05	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—epilepsy syndrome	4.89e-06	8.59e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM8—epilepsy syndrome	4.85e-06	8.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PGF—epilepsy syndrome	4.85e-06	8.52e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR2—epilepsy syndrome	4.84e-06	8.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—SST—epilepsy syndrome	4.84e-06	8.5e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HSD17B4—epilepsy syndrome	4.79e-06	8.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR7—epilepsy syndrome	4.79e-06	8.43e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AKT1—epilepsy syndrome	4.78e-06	8.41e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HBEGF—epilepsy syndrome	4.76e-06	8.37e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—POMC—epilepsy syndrome	4.75e-06	8.34e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CASP3—epilepsy syndrome	4.74e-06	8.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRA2A—epilepsy syndrome	4.73e-06	8.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CDC42—epilepsy syndrome	4.69e-06	8.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GAL—epilepsy syndrome	4.69e-06	8.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GFAP—epilepsy syndrome	4.69e-06	8.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT3—epilepsy syndrome	4.67e-06	8.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL2—epilepsy syndrome	4.64e-06	8.17e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRM5—epilepsy syndrome	4.64e-06	8.16e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP2—epilepsy syndrome	4.64e-06	8.16e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CHRM3—epilepsy syndrome	4.64e-06	8.16e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GBE1—epilepsy syndrome	4.63e-06	8.14e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPP1R3C—epilepsy syndrome	4.63e-06	8.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GNAO1—epilepsy syndrome	4.62e-06	8.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—OPRD1—epilepsy syndrome	4.62e-06	8.13e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—JUN—epilepsy syndrome	4.6e-06	8.1e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT3—epilepsy syndrome	4.57e-06	8.03e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—BDKRB2—epilepsy syndrome	4.55e-06	7.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL12—epilepsy syndrome	4.55e-06	7.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AVP—epilepsy syndrome	4.54e-06	7.99e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—epilepsy syndrome	4.48e-06	7.88e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CNR1—epilepsy syndrome	4.46e-06	7.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CX3CR1—epilepsy syndrome	4.45e-06	7.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PLCB1—epilepsy syndrome	4.45e-06	7.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CHRM1—epilepsy syndrome	4.43e-06	7.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDYN—epilepsy syndrome	4.43e-06	7.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM1—epilepsy syndrome	4.43e-06	7.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR7—epilepsy syndrome	4.43e-06	7.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CHRM2—epilepsy syndrome	4.36e-06	7.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BDKRB1—epilepsy syndrome	4.36e-06	7.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CX3CL1—epilepsy syndrome	4.36e-06	7.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR7—epilepsy syndrome	4.35e-06	7.66e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ASAH1—epilepsy syndrome	4.35e-06	7.66e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AKT1—epilepsy syndrome	4.35e-06	7.64e-05	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—epilepsy syndrome	4.33e-06	7.61e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CDC42—epilepsy syndrome	4.26e-06	7.49e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GABBR1—epilepsy syndrome	4.24e-06	7.46e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—STXBP1—epilepsy syndrome	4.24e-06	7.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HBEGF—epilepsy syndrome	4.23e-06	7.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CDC42—epilepsy syndrome	4.17e-06	7.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GFAP—epilepsy syndrome	4.17e-06	7.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GAL—epilepsy syndrome	4.17e-06	7.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT3—epilepsy syndrome	4.15e-06	7.3e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SRC—epilepsy syndrome	4.13e-06	7.26e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NT5E—epilepsy syndrome	4.13e-06	7.26e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALAD—epilepsy syndrome	4.13e-06	7.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AVP—epilepsy syndrome	4.13e-06	7.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP2—epilepsy syndrome	4.12e-06	7.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CHRM3—epilepsy syndrome	4.12e-06	7.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRM5—epilepsy syndrome	4.12e-06	7.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRH3—epilepsy syndrome	4.07e-06	7.15e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AVP—epilepsy syndrome	4.04e-06	7.1e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—epilepsy syndrome	4.02e-06	7.07e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—OPRM1—epilepsy syndrome	4.01e-06	7.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CX3CR1—epilepsy syndrome	3.95e-06	6.95e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CACNA1A—epilepsy syndrome	3.94e-06	6.92e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALDH7A1—epilepsy syndrome	3.94e-06	6.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CHRM2—epilepsy syndrome	3.87e-06	6.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CX3CL1—epilepsy syndrome	3.87e-06	6.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BDKRB1—epilepsy syndrome	3.87e-06	6.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR5—epilepsy syndrome	3.86e-06	6.79e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ST3GAL3—epilepsy syndrome	3.85e-06	6.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CDC42—epilepsy syndrome	3.79e-06	6.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR3—epilepsy syndrome	3.78e-06	6.65e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—HTR2A—epilepsy syndrome	3.78e-06	6.65e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADSL—epilepsy syndrome	3.78e-06	6.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GABBR1—epilepsy syndrome	3.77e-06	6.63e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GLUL—epilepsy syndrome	3.7e-06	6.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NPY—epilepsy syndrome	3.69e-06	6.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ATP2A2—epilepsy syndrome	3.69e-06	6.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AVP—epilepsy syndrome	3.66e-06	6.44e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CACNA1D—epilepsy syndrome	3.63e-06	6.39e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRH3—epilepsy syndrome	3.61e-06	6.35e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGT—epilepsy syndrome	3.59e-06	6.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—OPRM1—epilepsy syndrome	3.56e-06	6.26e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CRH—epilepsy syndrome	3.56e-06	6.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—OXT—epilepsy syndrome	3.56e-06	6.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL3—epilepsy syndrome	3.56e-06	6.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL2—epilepsy syndrome	3.56e-06	6.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HSPB1—epilepsy syndrome	3.56e-06	6.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR5—epilepsy syndrome	3.51e-06	6.17e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HTR2A—epilepsy syndrome	3.43e-06	6.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR5—epilepsy syndrome	3.43e-06	6.03e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	3.4e-06	5.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR3—epilepsy syndrome	3.36e-06	5.91e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—HTR2A—epilepsy syndrome	3.36e-06	5.9e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PRKCB—epilepsy syndrome	3.31e-06	5.83e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC1—epilepsy syndrome	3.31e-06	5.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTK2B—epilepsy syndrome	3.31e-06	5.81e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AQP1—epilepsy syndrome	3.3e-06	5.8e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NPY—epilepsy syndrome	3.27e-06	5.76e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ATP2A2—epilepsy syndrome	3.27e-06	5.76e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGT—epilepsy syndrome	3.26e-06	5.73e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR2—epilepsy syndrome	3.22e-06	5.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NTRK2—epilepsy syndrome	3.22e-06	5.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SST—epilepsy syndrome	3.22e-06	5.66e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DUSP6—epilepsy syndrome	3.19e-06	5.61e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGT—epilepsy syndrome	3.19e-06	5.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL2—epilepsy syndrome	3.16e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HSPB1—epilepsy syndrome	3.16e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—OXT—epilepsy syndrome	3.16e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CRH—epilepsy syndrome	3.16e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL3—epilepsy syndrome	3.16e-06	5.55e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRA2A—epilepsy syndrome	3.15e-06	5.53e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLAT—epilepsy syndrome	3.13e-06	5.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR5—epilepsy syndrome	3.12e-06	5.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HTR2A—epilepsy syndrome	3.05e-06	5.36e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BDKRB2—epilepsy syndrome	3.02e-06	5.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL12—epilepsy syndrome	3.02e-06	5.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—POMC—epilepsy syndrome	3.02e-06	5.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PRKCB—epilepsy syndrome	3.01e-06	5.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6ST—epilepsy syndrome	3e-06	5.27e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	2.98e-06	5.25e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	2.98e-06	5.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JUNB—epilepsy syndrome	2.97e-06	5.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CNR1—epilepsy syndrome	2.97e-06	5.22e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLCB1—epilepsy syndrome	2.96e-06	5.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PRKCB—epilepsy syndrome	2.94e-06	5.18e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC1—epilepsy syndrome	2.94e-06	5.16e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTK2B—epilepsy syndrome	2.94e-06	5.16e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR7—epilepsy syndrome	2.9e-06	5.09e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGT—epilepsy syndrome	2.89e-06	5.09e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SST—epilepsy syndrome	2.86e-06	5.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NTRK2—epilepsy syndrome	2.86e-06	5.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR2—epilepsy syndrome	2.86e-06	5.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DUSP6—epilepsy syndrome	2.83e-06	4.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HBEGF—epilepsy syndrome	2.81e-06	4.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRA2A—epilepsy syndrome	2.8e-06	4.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLAT—epilepsy syndrome	2.78e-06	4.9e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT3—epilepsy syndrome	2.76e-06	4.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—POMC—epilepsy syndrome	2.74e-06	4.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADAM10—epilepsy syndrome	2.7e-06	4.74e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BDKRB2—epilepsy syndrome	2.69e-06	4.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL12—epilepsy syndrome	2.69e-06	4.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL2—epilepsy syndrome	2.68e-06	4.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—POMC—epilepsy syndrome	2.68e-06	4.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PRKCB—epilepsy syndrome	2.67e-06	4.7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6ST—epilepsy syndrome	2.66e-06	4.68e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JUNB—epilepsy syndrome	2.64e-06	4.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CNR1—epilepsy syndrome	2.64e-06	4.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLCB1—epilepsy syndrome	2.63e-06	4.62e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR7—epilepsy syndrome	2.57e-06	4.52e-05	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—epilepsy syndrome	2.57e-06	4.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—S100B—epilepsy syndrome	2.55e-06	4.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SOCS3—epilepsy syndrome	2.52e-06	4.44e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDC42—epilepsy syndrome	2.52e-06	4.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HBEGF—epilepsy syndrome	2.5e-06	4.39e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT3—epilepsy syndrome	2.45e-06	4.31e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AVP—epilepsy syndrome	2.44e-06	4.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	2.44e-06	4.28e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	2.43e-06	4.28e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	2.39e-06	4.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	2.38e-06	4.19e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	2.37e-06	4.17e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	2.36e-06	4.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HES1—epilepsy syndrome	2.3e-06	4.05e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	2.26e-06	3.98e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	2.24e-06	3.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FYN—epilepsy syndrome	2.24e-06	3.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	2.24e-06	3.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—H2AFX—epilepsy syndrome	2.23e-06	3.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MEF2C—epilepsy syndrome	2.23e-06	3.92e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	2.16e-06	3.81e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—YWHAZ—epilepsy syndrome	2.15e-06	3.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NGF—epilepsy syndrome	2.13e-06	3.75e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR5—epilepsy syndrome	2.07e-06	3.64e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	2.05e-06	3.6e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HTR2A—epilepsy syndrome	2.03e-06	3.57e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	2.02e-06	3.56e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BCHE—epilepsy syndrome	2.02e-06	3.54e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	1.99e-06	3.5e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	1.98e-06	3.49e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	1.98e-06	3.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC2—epilepsy syndrome	1.93e-06	3.39e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGT—epilepsy syndrome	1.92e-06	3.38e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.92e-06	3.38e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	1.91e-06	3.37e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.9e-06	3.34e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TH—epilepsy syndrome	1.9e-06	3.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	1.89e-06	3.33e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOE—epilepsy syndrome	1.89e-06	3.32e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KDR—epilepsy syndrome	1.85e-06	3.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	1.84e-06	3.24e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	1.8e-06	3.17e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKCB—epilepsy syndrome	1.78e-06	3.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6ST—epilepsy syndrome	1.77e-06	3.11e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	1.71e-06	3.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	1.71e-06	3.01e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	1.67e-06	2.94e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	1.64e-06	2.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—POMC—epilepsy syndrome	1.62e-06	2.85e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL2—epilepsy syndrome	1.58e-06	2.79e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.58e-06	2.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	1.58e-06	2.78e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	1.57e-06	2.77e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.56e-06	2.74e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.52e-06	2.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	1.44e-06	2.53e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGF2—epilepsy syndrome	1.43e-06	2.52e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.41e-06	2.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	1.41e-06	2.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RELA—epilepsy syndrome	1.33e-06	2.34e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MTOR—epilepsy syndrome	1.3e-06	2.29e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	1.27e-06	2.24e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AGT—epilepsy syndrome	1.24e-06	2.18e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOE—epilepsy syndrome	1.21e-06	2.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—epilepsy syndrome	1.21e-06	2.13e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP3—epilepsy syndrome	1.2e-06	2.11e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	1.18e-06	2.08e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JUN—epilepsy syndrome	1.16e-06	2.05e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	1.16e-06	2.04e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—epilepsy syndrome	1.13e-06	1.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—epilepsy syndrome	1.1e-06	1.93e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.08e-06	1.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	1.07e-06	1.87e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SRC—epilepsy syndrome	1.04e-06	1.84e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—POMC—epilepsy syndrome	1.04e-06	1.83e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	1.03e-06	1.82e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—epilepsy syndrome	1.02e-06	1.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	1.01e-06	1.77e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	9.76e-07	1.72e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—epilepsy syndrome	9.5e-07	1.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	9.28e-07	1.63e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	9.04e-07	1.59e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	8.31e-07	1.46e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—epilepsy syndrome	6.49e-07	1.14e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	5.77e-07	1.01e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—epilepsy syndrome	4.18e-07	7.34e-06	CbGpPWpGaD
